EP0553235A4 - - Google Patents
Info
- Publication number
- EP0553235A4 EP0553235A4 EP19910919436 EP91919436A EP0553235A4 EP 0553235 A4 EP0553235 A4 EP 0553235A4 EP 19910919436 EP19910919436 EP 19910919436 EP 91919436 A EP91919436 A EP 91919436A EP 0553235 A4 EP0553235 A4 EP 0553235A4
- Authority
- EP
- European Patent Office
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59095690A | 1990-10-01 | 1990-10-01 | |
| US590956 | 1990-10-01 | ||
| US72270091A | 1991-06-28 | 1991-06-28 | |
| US722700 | 1991-06-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0553235A1 EP0553235A1 (en) | 1993-08-04 |
| EP0553235A4 true EP0553235A4 (en) | 1994-02-09 |
Family
ID=27081003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP91919436A Withdrawn EP0553235A1 (en) | 1990-10-01 | 1991-09-27 | Targeting viruses and cells for selective internalization by cells |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0553235A1 (en) |
| JP (1) | JPH07500961A (en) |
| AU (1) | AU660629B2 (en) |
| CA (1) | CA2092323A1 (en) |
| WO (1) | WO1992006180A1 (en) |
Families Citing this family (182)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550561B1 (en) | 1991-05-16 | 2009-06-23 | Cold Spring Harbor Laboratory | p16INK4 polypeptides |
| US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
| US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| SE503225C2 (en) * | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antibody complex for introduction of virus into mammalian cells |
| US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
| WO1993022433A2 (en) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
| GB9213601D0 (en) * | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
| WO1994006923A1 (en) * | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells |
| US5962316A (en) * | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
| US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
| GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| WO1994011524A1 (en) | 1992-11-09 | 1994-05-26 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Targetable vector particles |
| US5869331A (en) * | 1992-11-20 | 1999-02-09 | University Of Medicine & Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| JPH08504098A (en) * | 1992-11-20 | 1996-05-07 | ユニバーシティー オブ メディスン アンド デンティストリー オブ ニュー ジャージー | Cell-type-specific gene transfer using a retrovirus vector containing an antibody-envelope fusion protein |
| US6534051B1 (en) | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| US6331390B1 (en) | 1992-12-17 | 2001-12-18 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
| US6043030A (en) * | 1992-12-17 | 2000-03-28 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
| DE4311651A1 (en) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
| US5645829A (en) * | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US7691632B2 (en) | 1993-11-18 | 2010-04-06 | Cold Spring Harbor Laboratory | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression |
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
| ATE200105T1 (en) * | 1994-05-13 | 2001-04-15 | Chiron Corp | METHODS AND COMPOSITIONS AS VEHICLES FOR THE TARGETED INTRODUCTION OF GENES |
| US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
| US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
| US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| US7026116B1 (en) | 1996-04-04 | 2006-04-11 | Bio-Rad Laboratories, Inc. | Polymorphisms in the region of the human hemochromatosis gene |
| US6140305A (en) | 1996-04-04 | 2000-10-31 | Bio-Rad Laboratories, Inc. | Hereditary hemochromatosis gene products |
| US6849399B1 (en) | 1996-05-23 | 2005-02-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for diagnosis and treatment of iron misregulation diseases |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6074850A (en) * | 1996-11-15 | 2000-06-13 | Canji, Inc. | Retinoblastoma fusion polypeptides |
| HU226662B1 (en) | 1996-11-15 | 2009-06-29 | Canji | Nucleic acids coding for ezf-rb fusion polypeptides and expression vectors containing the same |
| WO1998044938A1 (en) | 1997-04-10 | 1998-10-15 | University Of Southern California | Modified proteins which bind extracellular matrix components |
| US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
| AU7727298A (en) * | 1997-06-06 | 1998-12-21 | Regents Of The University Of Michigan, The | Neuregulin response element and uses therefor |
| DE69838584T2 (en) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE |
| EP1068357B2 (en) | 1998-03-30 | 2014-12-10 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| AU753995B2 (en) | 1998-04-07 | 2002-10-31 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| AU1628800A (en) | 1998-11-19 | 2000-06-05 | Georgetown University | Systemic viral/ligand gene delivery system and gene therapy |
| AU3501700A (en) | 1999-02-26 | 2000-09-14 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| GB9908195D0 (en) | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| AU5011400A (en) | 1999-05-14 | 2000-12-05 | Arbor Vita Corporation | Molecular interactions in t cells |
| US20020064520A1 (en) * | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
| RU2002113076A (en) | 1999-11-18 | 2004-03-10 | Корвас Интернэшнл, Инк. (Us) | Nucleic acids encoding endotheliases, endotheliases and their use |
| NZ539430A (en) | 1999-12-10 | 2006-09-29 | Invitrogen Corp | Use of multiple recombination sites with unique specificity in recombinational cloning |
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| US7348014B2 (en) | 2000-04-14 | 2008-03-25 | Transgene, S.A. | Poxvirus with targeted infection specificity |
| CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| PT2281843T (en) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| EP1967206B1 (en) | 2000-08-30 | 2012-10-10 | Pfizer Products Inc. | Anti-IgE vaccines |
| JP4802401B2 (en) * | 2000-11-07 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | Poxvirus with targeted infection specificity |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| TWI327599B (en) | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
| US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
| EP1478751A4 (en) | 2001-03-30 | 2005-10-19 | Avigenics Inc | Avian lysozyme promoter |
| EP2228389B1 (en) | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
| FI116851B (en) | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Expression vector, its uses and process for its preparation and products containing it |
| US7064189B2 (en) | 2001-05-25 | 2006-06-20 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7449562B2 (en) | 2001-06-29 | 2008-11-11 | Novartis Ag | PERV screening method and use thereof |
| US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
| ES2462740T3 (en) | 2001-11-26 | 2014-05-26 | Laboratoire Biodim | Protein-protein interactions in human immunodeficiency virus |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| ES2373547T3 (en) | 2002-02-13 | 2012-02-06 | American Diagnostica, Inc. | METHODS FOR SELECTING TREATMENT REGIMES AND FORECASTING RESULTS IN PATIENTS WITH BREAST CANCER. |
| US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
| AU2003226230A1 (en) * | 2002-04-02 | 2003-10-20 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
| JP2005535572A (en) | 2002-04-12 | 2005-11-24 | メディミューン，インコーポレーテッド | Recombinant anti-interleukin-9 antibody |
| ES2381617T5 (en) | 2002-08-14 | 2016-02-24 | Macrogenics, Inc. | Specific antibodies against FcgammaRIIB and its procedures for use |
| EP2298874A1 (en) | 2002-12-16 | 2011-03-23 | Halozyme, Inc. | Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US8021833B2 (en) | 2003-02-12 | 2011-09-20 | Functional Genetics, Inc. | Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| CA2521826C (en) | 2003-04-11 | 2013-08-06 | Jennifer L. Reed | Recombinant il-9 antibodies and uses thereof |
| CN103937827A (en) | 2003-06-13 | 2014-07-23 | 新泽西内科与牙科大学 | RNA interferases and methods of use thereof |
| EP1644408A1 (en) | 2003-07-15 | 2006-04-12 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
| AU2004263896A1 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| WO2005032572A2 (en) | 2003-10-03 | 2005-04-14 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
| US20050227251A1 (en) | 2003-10-23 | 2005-10-13 | Robert Darnell | Method of purifying RNA binding protein-RNA complexes |
| EP1692262B1 (en) | 2003-10-27 | 2018-08-15 | Merck Sharp & Dohme Corp. | Method of designing sirnas for gene silencing |
| PL3718564T3 (en) | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Novel anti-il 13 antibodies and uses thereof |
| US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| EP1968565B1 (en) | 2004-04-16 | 2015-11-18 | Sun Baocun | Compositions and methods for inhibiting angiogenesis |
| CA2565450C (en) | 2004-05-07 | 2018-03-06 | Gyorgy Petrovics | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer |
| ES2660765T3 (en) | 2004-06-21 | 2018-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and routes expressed differentially in bipolar disorder and / or major depressive disorder |
| CA2574709A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| WO2006046994A2 (en) | 2004-07-30 | 2006-05-04 | Mount Sinai School Of Medicine Of New York University | Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk |
| JP2008518023A (en) | 2004-10-27 | 2008-05-29 | メディミューン，インコーポレーテッド | Regulation of antibody specificity by altering affinity for cognate antigens |
| JP2008520583A (en) | 2004-11-15 | 2008-06-19 | マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー | Compositions and methods for modifying WNT autocrine signaling |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| NZ556158A (en) | 2004-12-22 | 2010-04-30 | Auckland Uniservices Ltd | Trefoil factors and methods of treating proliferation disorders using same |
| US7615554B2 (en) | 2005-01-25 | 2009-11-10 | Prolexys Pharmaceuticals, Inc. | Erastin and erastin binding proteins, and uses thereof |
| CA2599589A1 (en) | 2005-02-07 | 2006-08-17 | Genenews,Inc. | Mild osteoarthritis biomarkers and uses thereof |
| WO2006102095A2 (en) | 2005-03-18 | 2006-09-28 | Medimmune, Inc. | Framework-shuffling of antibodies |
| EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CN101437539B (en) | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会（有限公司） | Blocking leukocyte emigration and inflammation by interfering with CD99l2 |
| CA2618681C (en) | 2005-08-10 | 2015-10-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US8249814B2 (en) | 2005-10-21 | 2012-08-21 | Genenews Inc. | Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject |
| KR20180002911A (en) | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | Use of complement pathway inhibitors to treat ocular diseases |
| JP5366554B2 (en) | 2005-11-12 | 2013-12-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | FGF2-related methods for diagnosing and treating depression |
| JP5367563B2 (en) | 2006-03-30 | 2013-12-11 | ピーティーシー セラピューティクス，インコーポレーテッド | Method for the production of functional proteins from DNA having nonsense mutations and treatment of disorders associated therewith |
| HUE030269T2 (en) | 2006-06-26 | 2017-04-28 | Macrogenics Inc | Fc riib-specific antibodies and methods of use thereof |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| SG170032A1 (en) | 2006-08-28 | 2011-04-29 | Kyowa Hakko Kirin Co Ltd | Antagonistic human light-specific human monoclonal antibodies |
| AU2007324128B2 (en) | 2006-10-10 | 2013-10-10 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations |
| JP2010506842A (en) | 2006-10-16 | 2010-03-04 | メディミューン，エルエルシー | Molecules with reduced half-life, compositions thereof and uses |
| CA2669095A1 (en) | 2006-11-15 | 2008-05-29 | Functional Genetics, Inc. | Anti-tsg101 antibodies and their uses for treatment of viral infections |
| TWI419904B (en) | 2006-12-18 | 2013-12-21 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| WO2008092041A2 (en) | 2007-01-24 | 2008-07-31 | Carnegie Mellon University | Optical biosensors |
| US8211858B2 (en) | 2007-04-27 | 2012-07-03 | The University Of Toledo | Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
| ES2702087T3 (en) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Covalent diabodies and their uses |
| CN101932602B (en) | 2007-06-27 | 2017-05-24 | 新加坡国立大学 | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
| UY31309A1 (en) | 2007-08-29 | 2009-03-31 | ANTI-CXCR5 HUMANIZED ANTIBODIES, DERIVED FROM THE SAME AND ITS USE | |
| US8669349B2 (en) | 2008-04-02 | 2014-03-11 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
| CN102046195A (en) | 2008-04-02 | 2011-05-04 | 宏观基因有限公司 | HER2/neu-specific antibodies and methods of using same |
| US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
| CA2726845C (en) | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| CN102282172B (en) | 2008-09-07 | 2014-02-19 | 台湾醣联生技医药股份有限公司 | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
| PL2786762T3 (en) | 2008-12-19 | 2019-09-30 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US20110312872A1 (en) | 2008-12-22 | 2011-12-22 | Universität Regensburg | Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
| EP2424978B1 (en) | 2009-04-27 | 2018-08-15 | Ottawa Hospital Research Institute | Compositions and methods for modulating stem cells and uses thereof |
| US20120134984A1 (en) | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof |
| JP5762408B2 (en) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
| US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
| CN102711772A (en) | 2009-10-16 | 2012-10-03 | 奥克兰联合服务有限公司 | Anti-neoplastic uses of artemin antagonists |
| US8916517B2 (en) | 2009-11-02 | 2014-12-23 | The Administrators Of The Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
| EP2496604B1 (en) | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
| US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
| US9995679B2 (en) | 2010-05-25 | 2018-06-12 | Carnegie Mellon University | Targeted probes of cellular physiology |
| EA027835B1 (en) | 2010-07-09 | 2017-09-29 | Круселл Холланд Б.В. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use thereof |
| JP5964300B2 (en) | 2010-08-02 | 2016-08-03 | マクロジェニクス，インコーポレーテッド | Covalently bonded diabody and its use |
| WO2012092299A1 (en) | 2010-12-27 | 2012-07-05 | Brown University | Therapeutic and diagnostic methods involving biglycan and utrophin |
| US10130687B2 (en) | 2011-01-05 | 2018-11-20 | Rhode Island Hospital | Compositions and methods for the treatment of orthopedic disease or injury |
| EA201391753A1 (en) | 2011-05-21 | 2014-08-29 | Макродженикс, Инк. | DOMAINS CONNECTING WITH DEIMMUNIZED SERUM AND THEIR APPLICATION TO INCREASE THE TIME OF HALF-DURATION |
| BR112014006321A2 (en) | 2011-09-16 | 2017-04-11 | Fate Therapeutics Inc | wnt compositions and therapeutic uses of such composition |
| US9732130B2 (en) | 2011-09-16 | 2017-08-15 | Ottawa Hospital Research Institute | WNT7A compositions and method of using the same |
| CN108530535B (en) | 2012-02-15 | 2021-02-26 | 诺和诺德股份有限公司 | Antibody binding to peptidoglycan-recognizing protein 1 |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| LT2814844T (en) | 2012-02-15 | 2017-10-25 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| WO2014006063A2 (en) | 2012-07-02 | 2014-01-09 | Medizinische Universität Wien | Complement split product c4d for the treatment of inflammatory conditions |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| WO2014120975A1 (en) | 2013-02-01 | 2014-08-07 | California Institute Of Technology | Antibody-mediated immunocontraception |
| EP3110974A4 (en) | 2014-02-24 | 2018-01-24 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
| EP3142700B1 (en) | 2014-05-16 | 2021-03-03 | Medimmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| US9458464B2 (en) | 2014-06-23 | 2016-10-04 | The Johns Hopkins University | Treatment of neuropathic pain |
| SG10201913702WA (en) | 2014-07-17 | 2020-03-30 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
| CN107429075B (en) | 2014-11-17 | 2022-11-01 | 卡内基梅隆大学 | Activatable two-component photosensitizer |
| US10729790B2 (en) | 2015-05-26 | 2020-08-04 | Salk Institute For Biological Studies | Motor neuron-specific expression vectors |
| US9920100B2 (en) | 2015-06-05 | 2018-03-20 | The Chinese University Of Hong Kong | Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy |
| WO2017182981A1 (en) | 2016-04-20 | 2017-10-26 | Washington University | Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity |
| CN111936520A (en) | 2018-04-02 | 2020-11-13 | 百时美施贵宝公司 | anti-TREM-1 antibodies and uses thereof |
| US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
| GB201914296D0 (en) | 2019-10-03 | 2019-11-20 | Univ Oxford Innovation Ltd | Treatment |
| EP4281034A1 (en) | 2021-01-24 | 2023-11-29 | Forrest, Michael, David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
| EP4337770A1 (en) | 2021-05-13 | 2024-03-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Compositions and methods for treating sickle cell diseases |
| CA3226402A1 (en) | 2021-07-19 | 2023-01-26 | Dounia ABBADI | Adeno-associated viral vector compositions and methods of promoting muscle regeneration |
| WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| US20230227545A1 (en) | 2022-01-07 | 2023-07-20 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
| WO2023146807A1 (en) | 2022-01-25 | 2023-08-03 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
-
1991
- 1991-09-27 AU AU88603/91A patent/AU660629B2/en not_active Ceased
- 1991-09-27 WO PCT/US1991/007103 patent/WO1992006180A1/en not_active Application Discontinuation
- 1991-09-27 JP JP3517570A patent/JPH07500961A/en active Pending
- 1991-09-27 EP EP91919436A patent/EP0553235A1/en not_active Withdrawn
- 1991-09-27 CA CA 2092323 patent/CA2092323A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
Non-Patent Citations (3)
| Title |
|---|
| FILE SERVER STN KARLSRUHE,FILE MEDLINE ABSTRACT NO.79131701 & J GEN VIROL, (1978 DEC) 41(3) 447-57 * |
| NEDA ET AL: "CHEMICAL MODIFICATION OF AN ECOTROPIC MURINE LEUKEMIA VIRUS RESULTS IN REDIRECTION OF ITS TARGET CELL SPECIFICITY", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991 (1991-08-05), BALTIMORE,USA, pages 14143 - 14146 * |
| See also references of WO9206180A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992006180A1 (en) | 1992-04-16 |
| AU660629B2 (en) | 1995-07-06 |
| JPH07500961A (en) | 1995-02-02 |
| AU8860391A (en) | 1992-04-28 |
| CA2092323A1 (en) | 1992-04-02 |
| EP0553235A1 (en) | 1993-08-04 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19930419 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
| RHK1 | Main classification (correction) |
Ipc: C12N 15/87 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19931220 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19960131 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19990401 |